TY - JOUR
T1 - The FDA-approved drug sofosbuvir inhibits Zika virus infection
AU - Bullard-Feibelman, Kristen M.
AU - Govero, Jennifer
AU - Zhu, Zhe
AU - Salazar, Vanessa
AU - Veselinovic, Milena
AU - Diamond, Michael S.
AU - Geiss, Brian J.
N1 - Funding Information:
This work was in part supported by grants from the Colorado State University College Research Council , NIH R01 AI073755 to M.S.D., and NIH R01 AI114675 to B.J.G. We thank Dr. Jeremy Rich for support of Dr. Zhe Zhu.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with severe cases causing Guillain-Barré syndrome, congenital malformations, and microcephaly. Currently, there is no available vaccine or therapy to prevent or treat ZIKV infection. We evaluated whether sofosbuvir, an FDA-approved nucleotide polymerase inhibitor for the distantly related hepatitis C virus, could have antiviral activity against ZIKV infection. Cell culture studies established that sofosbuvir efficiently inhibits replication and infection of several ZIKV strains in multiple human tumor cell lines and isolated human fetal-derived neuronal stem cells. Moreover, oral treatment with sofosbuvir protected against ZIKV-induced death in mice. These results suggest that sofosbuvir may be a candidate for further evaluation as a therapy against ZIKV infection in humans.
AB - The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with severe cases causing Guillain-Barré syndrome, congenital malformations, and microcephaly. Currently, there is no available vaccine or therapy to prevent or treat ZIKV infection. We evaluated whether sofosbuvir, an FDA-approved nucleotide polymerase inhibitor for the distantly related hepatitis C virus, could have antiviral activity against ZIKV infection. Cell culture studies established that sofosbuvir efficiently inhibits replication and infection of several ZIKV strains in multiple human tumor cell lines and isolated human fetal-derived neuronal stem cells. Moreover, oral treatment with sofosbuvir protected against ZIKV-induced death in mice. These results suggest that sofosbuvir may be a candidate for further evaluation as a therapy against ZIKV infection in humans.
UR - http://www.scopus.com/inward/record.url?scp=85000415085&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2016.11.023
DO - 10.1016/j.antiviral.2016.11.023
M3 - Article
C2 - 27902933
AN - SCOPUS:85000415085
SN - 0166-3542
VL - 137
SP - 134
EP - 140
JO - Antiviral Research
JF - Antiviral Research
ER -